SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

United States Commodity Funds LLC - United States Oil Fund

United States Oil Fund

USO is trending as mounting geopolitical tensions with Iran, coupled with a significant US military buildup in the Middle East, ignite intense community speculation about potential oil supply disruptions and a "war premium" for crude.

SSgA Active Trust - State Street Utilities Select Sector SPDR ETF

Utilities Select Sector SPDR Fund

The Utilities Select Sector SPDR Fund (XLU) is trending due to its dual appeal as a traditional defensive safe haven and a significant beneficiary of the escalating electricity demands from AI data centers. The community is actively discussing its robust performance and strategic positioning amidst broader market shifts.

Tidal Trust III - Fundstrat Granny Shots US Large Cap ETF

Fundstrat Granny Shots US Large Cap ETF

Fundstrat Granny Shots US Large Cap ETF is trending due to its rapid growth, surpassing $3 billion in assets under management and becoming one of the fastest-growing active ETFs. The community is actively discussing Tom Lee's market insights and the fund's strong performance, often weighing it against its notable expense ratio.

Gemini Space Station, Inc. is a holding company, which offers a mobile and web based crypto asset exchange platform, proprietary wallet infrastructure and custody solutions, over-the-counter trading solutions tailored to institutions and professionals, a digital art auction platform, a proprietary United States dollar backed stablecoin, and a credit card product that offers crypto asset rewards on customer purchases. The company was founded by Tyler Winklevoss and Cameron Winklevoss in 2014 and is headquartered in New York, NY.

Gemini Space Station Inc. - Ordinary Shares- Class A

Gemini Space Station

Gemini Space Station is trending as it grapples with the recent departure of its COO, CFO, and CLO, alongside weak preliminary guidance and a strategic exit from international markets. This corporate overhaul fuels community concern and frustration regarding the company's stability and prior IPO performance, despite some bullish outlooks on its prediction market and crypto potential.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is trending after announcing positive Phase 2 S-OLARIS trial results for sonelokimab in axial spondyloarthritis, showcasing "disease modifying" potential and "best-in-class" efficacy. The community anticipates a significant re-valuation and potential short squeeze, fueled by strong financial positioning and upcoming Investor Day presentations.

The Mullen Army Token originated from a dedicated community of retail investors who faced challenges in the traditional stock market. We united to create a cryptocurrency that embodies our principles and aspirations for a fair financial system.     We provide a platform for retail investors to engage in a transparent and fair financial market. Our efforts include grassroots marketing, community engagement, and educational content to empower our investors.

MullenArmy

Mullen is trending following the launch of its 'Mullen Army' cryptocurrency token. The community is largely discussing this development with intense skepticism, widely perceiving it as another potential scam and an extension of the company's controversial stock history marked by severe dilution and reverse splits.

Electro Optic Systems Holdings Ltd. develops and produces products incorporating advanced electro-optic technologies for the aerospace market. It operates through the Space Systems and Defence Systems segments. The Space Systems segment is involved in ground products available to support the Australian and international space markets. The Defence Systems segment develops, manufactures, and markets advanced fire control, surveillance, and weapon systems to approved military customers. The company was founded by Benny Allan Greene in 1983 and is headquartered in Symonston, Australia.

Electro Optic Systems Holdings Ltd

Electro Optic Systems is trending as a potential landmark German defense contract for its cost-effective laser systems and a strategic re-listing in Europe capture market attention, aiming to capitalize on surging defense spending. The community is also highlighting new US Army orders for its Slinger counter-drone technology and the stock's resilience against a short seller report.

Super Group (SGHC) Ltd. is a global digital gaming company, which engages in the global online sports betting and gaming businesses, Betway, a premier online sports betting brand, and Spin, a multi-brand online casino offering. It operates through the following segments: Betway, Spin, and Other. The Betway segment focuses on the ingle brand online sportsbook and online casino focused business with a global footprint and strategic partnerships. The Spin segment relates to the multi-brand online casino focused business with established market leadership in high-growth markets. The company was founded in July 2020 and is headquartered in St. Peter Port, the United Kingdom.

Super Group (SGHC) Limited

Super Group (SGHC) is trending amid discussions of a potential short squeeze, fueled by recent strong financial results that include Q3 earnings beats, raised guidance, and a special dividend. The community highlights its debt-free, profitable status and global focus, particularly in Africa and Europe, positioning it as an undervalued player in the iGaming sector despite broader market volatility.

CVRx, Inc. engages in developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. It operates through the following geographical segments: United States, Germany, and Other Countries. The company was founded by Robert S. Kieval and Tyler P. Lipschultz in August 2001 and is headquartered in Minneapolis, MN.

CVRx Inc

CVRx shares are currently trending due to a preliminary Q1 revenue guidance miss that has sparked concerns regarding sales force productivity and rising operating expenses. However, many in the community view the resulting sharp decline as a buying opportunity, highlighting the company's innovative Barostim therapy, strong gross margins, and recent positive long-term reimbursement developments.

The Clorox Co. engages in the manufacture and marketing of consumer and professional products. It operates through the following business segments: Health and Wellness, Household, Lifestyle, and International. The Health and Wellness segment consists of cleaning products, professional products and vitamins, minerals and supplements mainly marketed and sold in the United States. The Household segments consists of bags and wraps, grilling products and cat litter marketed and sold in the United States. The Lifestyle segment refers to food, natural personal care products and water-filtration products marketed and sold in the United States. The International segment covers products sold outside the United States, excluding natural personal care products. The company was founded by Edward Hughes, Charles Husband, William Hussey, Rufus Myers, and Archibald Taft on May 3, 1913 and is headquartered in Oakland, CA.

Clorox Co.

Clorox is garnering significant attention following its acquisition of Purell maker GOJO Industries, which the community views as a strategic move to reinforce its core hygiene business and enhance its long-term portfolio quality amidst its established reputation as a resilient, dividend-paying defensive stock.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Oncobiologics, Inc. (OTLK) Reports Q1 Loss, Misses Revenue Estimates

Oncobiologics (OTLK) delivered earnings and revenue surprises of -26.95% and -131.38%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?

Outlook Therapeutics Earnings Report: Q1 Overview

OTLK Stock Crashes 67% in a Week: Here's What You Need to Know

Outlook Therapeutics stock plunges 67% in a week after the FDA issues a third CRL rejecting its ONS-5010 BLA for wet AMD, again seeking confirmatory data.

Wall Street Zen Downgrades Oncobiologics (NASDAQ:OTLK) to Sell

Wall Street Zen downgraded Oncobiologics from a "hold" rating to a "sell" rating in a research report on Saturday...

Futures Blast Off On First Day Of 2026 With Europe, Asia At Records

Futures Blast Off On First Day Of 2026 With Europe, Asia At Records Stocks are set to break a four-day losing streak as markets start the new year with a bang across global markets, boosted by the...

<ul class="summary-bullets"><li>The FDA said it cannot approve the application in its present form for the treatment of wet age-related macular degeneration.</li><li>This marked the second rejection for Outlook’s drug for wet AMD treatment in less than six months.</li><li>The CEO said, “We are disappointed and disagree with this decision.</li></ul>Shares of Outlook Therapeutics (<a href="https://stocktwits.com/symbol/OTLK">OTLK</a>) slumped more than 60% on Friday after it failed to secure U.S. Food and Drug Administration approval for its drug Lytenava, which is intended to treat wet age-related macular degeneration (wet AMD), a chronic eye disorder.This marked the second rejection for Outlook’s drug for wet AMD treatment in less than six months. In August, the FDA declined to approve the drug, citing insufficient evidence of effectiveness, and recommended that the company submit additional data to support its application.In the Complete Response Letter (CRL), the FDA noted that the additional mechanistic and natural history data provided in the biologics license application (BLA) resubmission do not alter the previous review conclusion, adding that the FDA cannot approve the application in its present form for the treatment of wet age-related macular degeneration.“We are disappointed and disagree with this decision, but we remain fully committed to taking all necessary steps to receive approval in the United States,” Bob Jahr, Chief Executive Officer of Outlook Therapeutics, said in a statement.Lytenava has been granted marketing authorization by the European Commission in the EU and marketing authorization by the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK for the treatment of wet AMD.Age-related macular degeneration causes damage to the macula, a small area near the center of the retina, which is the part of the eye responsible for sharp, central vision. It is common among people aged 50 and older.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment around OTLK trended in ‘extremely bullish’ territory amid ‘extremely high’ message volumes.<figure class="image"><img style="aspect-ratio:636/66;" src="https://news.stocktwits-cdn.com/otlk_3_PNG_39a4a7c8e1.webp" alt="Retail sentiment around OTLK trended in ‘extremely bullish’ territory amid ‘extremely high’ message volumes." width="636" height="66"></figure>However, the latest blow from the FDA has disappointed retail traders, with one user saying, “Even if they have money, they have proven approval is beyond their abilities.”<figure class="image"><img style="aspect-ratio:651/132;" src="https://news.stocktwits-cdn.com/OTLK_USER_1_PNG_ebd1b97a3d.webp" alt="latest blow from the FDA has disappointed retail traders, with one user saying, “Even if they have money, they have proven approval is beyond their abilities.”" width="651" height="132"></figure> The FDA disapproval prompted users to believe the company would do cost-cutting. With one user saying to expect the next PR to be cost-cutting and layoffs, followed by dilution, and yet another reverse split.<img src="https://news.stocktwits-cdn.com/otlk_4_PNG_f4b526073b.webp" alt="otlk 4.PNG">Shares of Outlook Therapeutics were down nearly 17% in 2025.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com. &nbsp;

 In this photo illustration, the United States Food and Drug Administration (FDA) logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Outlook Therapeutics Tanks Over 60% On Another FDA Blow – Here’s How Retail Is Reacting 

OTLK Stock - The U.S. health regulatory agency, the FDA, rejected Outlook Therapeutics’ application for approval of its drug Lytenava, which is intended to treat wet AMD.

A Second FDA Rejection Sparked A Rout In Outlook Therapeutics Shares 

Equity

The U.S. health regulatory agency, the FDA, rejected Outlook Therapeutics’ application for approval of its drug Lytenava, which is intended to treat wet AMD.

Outlook Therapeutics Stock Sinks After FDA Rejects Eye Drug Again

Outlook Therapeutics' stock fell to a new low due to FDA rejection of its Lytenava filing for wet AMD. Efficacy evidence remains key issue.read more...

Outlook Therapeutics, Intelligent Bio Solutions And Other Big Stocks Moving Lower In Friday's Pre-Market Session

Oncobiologics, Inc. (NASDAQ:OTLK) Receives Consensus Rating of "Hold" from Analysts

Oncobiologics, Inc. (NASDAQ:OTLK - Get Free Report) has been assigned an average rating of "Hold" from the six analysts that are covering the firm, Marketbeat reports. One equities research analyst...

Oncobiologics (NASDAQ:OTLK) Stock Price Expected to Rise, Ascendiant Capital Markets Analyst Says

Ascendiant Capital Markets upped their target price on shares of Oncobiologics from $8.00 to $10.00 and gave the company a "buy" rating in a research note on Monday...

This account has been verified as an official OTLK representative.

Verified Account

Outlook Therapeutics

Outlook Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of ONS-5010/LYTENAVA. Its pipeline includes unmet patient needs, repackaged IV bevacizumab, and anti-VEGF. The company was founded by Pankaj Mohan on January 5, 2010 and is headquartered in Iselin, NJ.

OTLK
Outlook Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest OTLK News

OTLKOutlook Therapeutics Inc